Загрузка...
Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been emerged as the standard selection in non-small cell lung cancer (NSCLC) patients with EGFR sensitive mutations. However, primary or acquired resistance to EGFR-TKIs seems inevitable, especially to third-gen...
Сохранить в:
| Опубликовано в: : | BMC Cancer |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6368759/ https://ncbi.nlm.nih.gov/pubmed/30736738 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5352-7 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|